The Latest Cardiac and Vascular News
SAN CARLOS, Calif., May 11, 2018 /PRNewswire/ — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, filed its 10-Q for the three months ended March 31, 2018 with the Securities and Exchange Commission. First Quarter 2018 Financial Results: BioCardia reported a net loss of $3.6 million for the first quarter […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved national reimbursement coverage for the CardiAMP Chronic Myocardial Ischemia Trial. “We are thankful for the CMS decision to […]
SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ — BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart Journal. Titled “The CardiAMP Heart Failure Trial: A Randomized Controlled Pivotal Trial of High Dose Autologous Bone […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announced it filed its annual 10-K for the year ended December 31, 2017 with the Securities and Exchange Commission on Friday, March 16, 2018. BioCardia reported a net loss of $12.3 million […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the FDA has approved an Investigational Device Exemption for the CardiAMP Chronic Myocardial Ischemia (CMI) Trial to treat patients with refractory angina (RA). The CardiAMP Chronic Myocardial Ischemia Trial will be […]
SAN CARLOS, Calif.–(BUSINESS WIRE)-–BioCardia, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported filing a second Investigational Device Exemption with the FDA for the CardiAMP Chronic Myocardial Ischemia Trial to treat patients with refractory angina. This second potential indication for CardiAMP investigational cell therapy of […]
SAN CARLOS, Calif.–(BUSINESS WIRE)– BioCardia, Inc.[OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced a reverse split of its common stock, $0.001 par value, at a ratio of 1 for 12, effective November 2, 2017 (the “Effective Date”). The company’s common stock will begin […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure, today announced the issuance of United States Patent No. 9,775,963 entitled, “Steerable Endoluminal Devices and Methods.” BioCardia CEO Peter Altman, PhD stated, “This new patent […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the pre-specified interim analysis of safety outcomes for the first 10 patients treated in the Phase 3 trial of its […]
DALLAS & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the University of Miami Miller School of Medicine and co-sponsored by the company. The results showed a […]
